Literature DB >> 20804495

Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor.

Elodie Kara1, Hong Lin, Kjell Svensson, Anette M Johansson, Philip G Strange.   

Abstract

UNLABELLED: BACKGROUND AND PURPOSE; The two phenylpiperidines, OSU6162 and ACR16, have been proposed as novel drugs for the treatment of brain disorders, including schizophrenia and Huntington's disease, because of their putative dopamine stabilizing effects. Here we evaluated the activities of these compounds in a range of assays for the D(2) dopamine receptor in vitro. EXPERIMENTAL APPROACH: The affinities of these compounds for the D(2) dopamine receptor were evaluated in competition with [(3) H]spiperone and [(3) H]NPA. Agonist activity of these compounds was evaluated in terms of their ability to stimulate [(35) S]GTPγS binding. KEY
RESULTS: Both compounds had low affinities for inhibition of [(3) H]spiperone binding (pK(i) vs. [(3) H]spiperone, ACR16: <5, OSU6162: 5.36). Neither compound was able to stimulate [(35) S]GTPγS binding when assayed in the presence of Na(+) ions, but if the Na(+) ions were removed, both compounds were low-affinity, partial agonists (E(max) relative to dopamine: ACR16: 10.2%, OSU6162:54.3%). Schild analysis of the effects of OSU6162 to inhibit dopamine-stimulated [(35) S]GTPγS binding indicated Schild slopes of ∼0.9, suggesting little deviation from competitive inhibition. OSU6162 was, however, able to accelerate [(3) H]NPA dissociation from D(2) dopamine receptors, indicating some allosteric effects of this compound. CONCLUSIONS AND IMPLICATIONS: The two phenylpiperidines were low-affinity, low-efficacy partial agonists at the D(2) dopamine receptor in vitro, possibly exhibiting some allosteric effects. Comparing their in vitro and in vivo effects, the in vitro affinities were a reasonable guide to potencies in vivo. However, the lack of in vitro-in vivo correlation for agonist efficacy needs to be further addressed. LINKED ARTICLES: This article is part of a themed section on Analytical Receptor Pharmacology in Drug Discovery. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2010.161.issue-6.
© 2010 The Authors. British Journal of Pharmacology © 2010 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20804495      PMCID: PMC3000658          DOI: 10.1111/j.1476-5381.2010.01010.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation.

Authors:  J Wilson; H Lin; D Fu; J A Javitch; P G Strange
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

Review 2.  Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects.

Authors:  P G Strange
Journal:  Pharmacol Rev       Date:  2001-03       Impact factor: 25.468

3.  PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.

Authors:  N F Nichols; M G Cimini; J V Haas; B A Staton; J Tedroff; K A Svensson
Journal:  Neuropharmacology       Date:  2002-10       Impact factor: 5.250

4.  Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics.

Authors:  Elodie Kara; Hong Lin; Philip G Strange
Journal:  J Neurochem       Date:  2009-12-24       Impact factor: 5.372

5.  Differences in the ligand binding properties of the short and long versions of the D2 dopamine receptor.

Authors:  S W Castro; P G Strange
Journal:  J Neurochem       Date:  1993-01       Impact factor: 5.372

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  Regulation of porcine brain alpha 2-adrenergic receptors by Na+,H+ and inhibitors of Na+/H+ exchange.

Authors:  J M Nunnari; M G Repaske; S Brandon; E J Cragoe; L E Limbird
Journal:  J Biol Chem       Date:  1987-09-05       Impact factor: 5.157

8.  Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors.

Authors:  David J Roberts; Hong Lin; Philip G Strange
Journal:  Biochem Pharmacol       Date:  2004-05-01       Impact factor: 5.858

9.  The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition.

Authors:  Marie Nilsson; Arvid Carlsson; Katarina Rydén Markinhuhta; Clas Sonesson; Fredrik Pettersson; Maria Gullme; Maria L Carlsson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-07       Impact factor: 5.067

10.  Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line.

Authors:  G Hayes; T J Biden; L A Selbie; J Shine
Journal:  Mol Endocrinol       Date:  1992-06
View more
  10 in total

1.  II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.

Authors:  Ethan S Burstein; Maria L Carlsson; Michelle Owens; Jian-Nong Ma; Hans H Schiffer; Arvid Carlsson; Uli Hacksell
Journal:  J Neural Transm (Vienna)       Date:  2011-08-25       Impact factor: 3.575

2.  Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats.

Authors:  Johan P Rung; Emilia Rung; Anette M Johansson; Kjell Svensson; Arvid Carlsson; Maria L Carlsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

3.  I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors.

Authors:  Maria L Carlsson; Ethan S Burstein; Angélica Kloberg; Sarah Hansson; Arja Schedwin; Marie Nilsson; Johan P Rung; Arvid Carlsson
Journal:  J Neural Transm (Vienna)       Date:  2011-08-28       Impact factor: 3.575

4.  The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects.

Authors:  Nelleke Tolboom; Henk W Berendse; Josee E Leysen; Maqsood Yaqub; Bart N M van Berckel; Robert C Schuit; Mirthe M Ponsen; Esther Bakker; Nikie J Hoetjes; Albert D Windhorst; Maria L Carlsson; Adriaan A Lammertsma; Arvid Carlsson
Journal:  Neuropsychopharmacology       Date:  2014-08-05       Impact factor: 7.853

5.  Effects of the monoamine stabilizer (-)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity.

Authors:  Vívian T da Silveira; Jivago Röpke; Ana L Matosinhos; Ana C Issy; Elaine A Del Bel; Antônio C de Oliveira; Fabrício A Moreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-04-24       Impact factor: 3.000

6.  Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.

Authors:  Ferdinando Squitieri; Justo Garcia de Yebenes
Journal:  Drug Des Devel Ther       Date:  2015-10-28       Impact factor: 4.162

7.  The monoamine stabilizer (-)-OSU6162 counteracts downregulated dopamine output in the nucleus accumbens of long-term drinking Wistar rats.

Authors:  Kristin Feltmann; Ida Fredriksson; Malin Wirf; Björn Schilström; Pia Steensland
Journal:  Addict Biol       Date:  2015-10-14       Impact factor: 4.280

8.  Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.

Authors:  Kristoffer Sahlholm; Jurgen W A Sijbesma; Bram Maas; Chantal Kwizera; Daniel Marcellino; Nisha K Ramakrishnan; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Psychopharmacology (Berl)       Date:  2015-07-11       Impact factor: 4.530

Review 9.  Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.

Authors:  Andrea de Bartolomeis; Carmine Tomasetti; Felice Iasevoli
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

10.  The monoamine stabilizer (-)-OSU6162 prevents the alcohol deprivation effect and improves motor impulsive behavior in rats.

Authors:  Ida Fredriksson; Malin Wirf; Pia Steensland
Journal:  Addict Biol       Date:  2018-02-26       Impact factor: 4.280

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.